Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies
jRCT2080221810Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of emibetuzumab in Non-hematologic malignancy, lymphoma and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company.
02
Drugs
emibetuzumab
03
Conditions
Non-hematologic malignancylymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221810.